Instrument Inactif

Autres langues Clearmind Medicine Inc. Canadian Securities Exchange

Actions

Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders	17/04
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders	10/04
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders	10/04
Clearmind Medicine CEO Issues Letter to Shareholders	09/04
Clearmind Medicine Inc. Announces International Patent Application for Preventing and Treating Depression	27/03
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China	19/03
Clearmind Medicine Inc. Receives Divisional Patent Approval by the China National Intellectual Property Administration	19/03
Clearmind Medicine : Condensed Interim Consolidated Financial Statements - Form 6-K	19/03
Clearmind Medicine Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	18/03
SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals	08/03/22
Clearmind Medicine : Appoints Distinguished Addiction Experts Professor Wim van den Brink and Professor Gabriele Fischer to Its Scientific Advisory Board	14/10/21
Clearmind Medicine : to Host ‘Psychedelics for Alcoholism‘ Virtual Educational Event on October 20	01/10/21

Aucun résultat pour cette recherche